Results 181 to 190 of about 136,553 (347)

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong   +6 more
wiley   +1 more source

Virtual network sampling method using LinkedIn. [PDF]

open access: yesMethodsX, 2021
Kozłowski A   +3 more
europepmc   +1 more source

Impact of information technology in trade facilitation on small and medium-sized enterprises in Bangladesh [PDF]

open access: yes
This paper focuses specifically on one particular aspect of trade facilitation in the context of Bangladesh, i.e., impact on SMEs of IT in trade facilitation.
Muhammad Al Amin   +2 more
core  

Young people's occupational aspirations beyond the aspiration discourse: A sociocultural perspective

open access: yesBritish Educational Research Journal, EarlyView.
Abstract Young people's aspirations have been the focus of many educational, sociological and psychological studies. This paper argues, firstly, that the concept of aspirations holds greater generative potential than suggested by the policy‐oriented ‘aspiration discourse’.
Jelena Popov
wiley   +1 more source

New opportunities for bioscaffold‐enabled spinal cord injury repair

open access: yesBMEMat, EarlyView.
Schematic illustration of bioscaffolds for spinal cord injury repair. We summarize the effects of bioscaffold properties on SCI repair, highlight different types of bioscaffolds, various fabrication strategies, and in vivo transformations for the clinical development of SCI‐repairing bioscaffolds.
Xiaoqing Qi   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy